Anti-Human PDGF-R alpha Recombinant Antibody (Olaratumab)
CAT#: TAB-192
Recombinant monoclonal antibody to PDGF-R alpha. Olaratumab is a monoclonal antibody which is for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.
Published Data
Gene Expression
Figure 1 Olaratumab prevents ligand-induced phosphorylation of PDGFRa.
A–C, A-204 and HuO9 cells (A), which only express PDGFRa, G-402 and MG-63 cells (B), which express both PDGF receptors, or G-401 cells (C), which are PDGFRb positive, were treated with 1 mmol/L IgG or olaratumab for 15 minutes and then stimulated with individual PDGFs (5 nmol/L). Whole-cell lysates were probed for phosphorylation of PDGF receptors and downstream effectors AKT and ERK1/2.
Lowery, C. D., Blosser, W., Dowless, M., Knoche, S., Stephens, J., Li, H., ... & Guo, Q. (2018). Olaratumab exerts antitumor activity in preclinical models of pediatric bone and soft tissue tumors through inhibition of platelet-derived growth factor receptor α. Clinical Cancer Research, 24(4), 847-857.
Figure 2 Olaratumab reduces osteosarcoma and MRT cell invasion in vitro.
A–E, A-204 (A), HuO9 (B), G-402 (C), MG-63 (D), or G-401 cells (E) were evaluated for cell invasion using a simplified Boyden chamber assay. Cells were incubated with IgG or olaratumab; individual PDGFs (5 nmol/L each, with the exception of 25 nmol/L PDGF-DD) or FBS served as chemoattractants. After 48 hours, the number of invasive cells was quantified using a fluorescence-based method and normalized to the serum-free media (SFM) IgG control. Results are presented as the summary of duplicate (G-402) or triplicate experiments SEM. P values were calculated using the Student t test. Significance indicators: , P < 0.05, P < 0.001.
Lowery, C. D., Blosser, W., Dowless, M., Knoche, S., Stephens, J., Li, H., ... & Guo, Q. (2018). Olaratumab exerts antitumor activity in preclinical models of pediatric bone and soft tissue tumors through inhibition of platelet-derived growth factor receptor α. Clinical Cancer Research, 24(4), 847-857.
Figure 3 Olaratumab inhibits tumor growth in A-204 and HuO9 cell line–derived xenograft mouse models.
A and B, Mice with A-204 subcutaneous xenografts were treated with either 40 mg/kg IgG control or 40 mg/kg olaratumab three times weekly for 4 weeks. A, Average tumor volume SEM (n ¼ 11/group) during the treatment period is shown. B, Waterfall plot of %Dtumor/control or %regression for individual animals at day 30. One animal in the treatment arm was found dead on day 17 and was not included in downstream analysis. C and D, Mice bearing HuO9 subcutaneous xenografts were treated with olaratumab (60 mg/kg)/1E10 (20 mg/kg) twice weekly and/or cisplatin or doxorubicin (5 mg/kg) once weekly. Treatment began at day 44 (dotted line) and continued for 5 weeks. C, A single HuO9 in vivo experiment is displayed in two separate graphs with the same control and olaratumab/1E10 arms but different chemotherapy-containing arms containing chemotherapy (left, cisplatin; right, doxorubicin). The graph displays average tumor volume SEM (n ¼ 6/group). D, Waterfall plot of individual %Dtumor/control or %regression at day 60. P values for tumor growth curves are displayed in Supplementary Table S4. PD, progressive disease (>10% growth); SD, stable disease ( 50%–10% growth); PR, partial regression ( 50% and>14 mm3).
Lowery, C. D., Blosser, W., Dowless, M., Knoche, S., Stephens, J., Li, H., ... & Guo, Q. (2018). Olaratumab exerts antitumor activity in preclinical models of pediatric bone and soft tissue tumors through inhibition of platelet-derived growth factor receptor α. Clinical Cancer Research, 24(4), 847-857.
❮
❯
Subcellular Location
Figure 1 IF staining of human cell line CACO-2
Immunofluorescent staining of human cell line CACO-2 shows localization to nucleoplasm, plasma membrane & cell junctions.
* Image credit: Image credit: Human Protein Atlas v21.proteinatlas.org/images/4947/1030_B8_3_selected.jpg
Normal Tissue
Figure 2 IHC staining of human bone marrow
Immunohistochemical staining of human bone marrow shows moderate cytoplasmic positivity in megakaryocytes.
* Image credit: Image credit: Human Protein Atlas v21.proteinatlas.org/images/18143/ihc_selected.jpg
Normal Tissue
Figure 3 Cerebral cortex
Endothelial cells Staining: High Intensity: Strong Quantity:>75% Location: Cytoplasmic/ membranous
* Image credit: Image credit: Human Protein Atlas v21.proteinatlas.org/images/18143/43112_B_8_5.jpg
Normal Tissue
Figure 4 Colon
Enterocytes - Fibroblasts Staining: High Intensity: Strong
* Image credit: Image credit: Human Protein Atlas v21.proteinatlas.org/images/18143/43112_A_9_3.jpg
Normal Tissue
Figure 5 Kidney
Cells in glomeruli Staining: Medium Intensity: Moderate Quantity: 75%-25%
* Image credit: Image credit: Human Protein Atlas v21.proteinatlas.org/images/18143/43112_A_7_5.jpg
Normal Tissue
Figure 6 Bone marrow
Hematopoietic cells Staining: Low Intensity: Moderate Quantity: <25% Location: Cytoplasmic/ membranous
* Image credit: Image credit: Human Protein Atlas v21.proteinatlas.org/images/18143/43112_B_5_4.jpg
RNA Expression
Figure 7 RNA cell line category: Cell line enhanced (ASC diff, ASC TERT1, BJ hTERT+, fHDF/TERT166, HHSteC, HSkMC)
Cell lines ordered by descending RNA expression order.
* Image credit: Image credit: Human Protein Atlas v21.proteinatlas.org/ENSG00000134853-PDGFRA
❮
❯
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Human
- Derivation
- Human
- Type
- IgG1 - kappa
- Specificity
- Tested positive against native human antigen.
- Species Reactivity
- Human
- Applications
- IF, IP, Neut, FuncS, ELISA, FC, ICC
- CAS
- 1024603-93-7
- Generic Name
- Olaratumab
- MW
- 147.2 kDa
- Related Disease
- Ovarian cancers
Product Property
- Purity
- Purity >95% by SDS-PAGE.
- Storage
- Store at -20°C for long-term storage. Store at 2-8°C for up to one month. Avoid freeze/thaw cycles.
Applications
- Application Notes
- The PDGFRA antibody has been reported in applications of WB, Invasion, Inhib.
Target
- Alternative Names
- Olaratumab;1024603-93-7;IMC-3G3;IMC3G3;PDGFRA;platelet-derived growth factor receptor, alpha polypeptide;platelet-derived growth factor receptor alpha;CD140a;PDGFR2;PDGFR-alpha;PDGF-R-alpha;CD140a antigen;PDGFRA/BCR fusion;CD140 antigen-like family member
- Gene ID
- 5156
- UniProt ID
- P16234
REVIEWS AND Q&AS
CITATIONS
RESOURCES
DOWNLOADS
RELATED PRODUCTS
Inquiry
Navs
Customer Review
There are currently no Customer reviews or questions for TAB-192. Click the button above to contact us or submit your feedback about this product.
Cite This Product
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-192, RRID: AB_3111862)
Copy citation
Submit Your Publication
Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.
Biosimilar Overview
Please refer to Olaratumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Olaratumab.
Downloadable Resources
Download resources about recombinant antibody development and antibody engineering to boost your research.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Datasheet
MSDS
COA
Certificate of Analysis LookupTo download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number:
Protocol & Troubleshooting
We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.
See other products for "Olaratumab"
Afuco™ Anti-PDGFRA ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-192)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to PDGF-R alpha. It is a monoclonal antibody which is for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.
DrugMonitor™ Anti-Olaratumab Antibody (VS-1224-YC837)Olaratumab is an antibody that inhibits the platelet-derived growth factor receptor alpha, used in combination with doxorubicin for treating certain types of soft tissue sarcoma (STS). The DrugMonitor™ Anti-Olaratumab Antibody (VS-1224-YC837) is an anti-drug antibody (ADA) against Olaratumab. This drug-based antibody is raised in mice immunized with the Olaratumab. The anti-Olaratumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Olaratumab in samples.
See other products for "PDGFRA"
Select a product category from the dropdown menu below to view related products.
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOB-1475z | Mouse Anti-PDGFRA Recombinant Antibody (clone 27F5) | WB, ELISA, FC, ICC, IF, IHC | Mouse IgG1 |
| HPAB-0233LY | Human Anti-PDGFRA Recombinant Antibody (clone 2.451.1.1) | Inhib, FC | Human IgG1 |
| HPAB-0234LY | Human Anti-PDGFRA Recombinant Antibody (clone 2.449.1.3) | Inhib, FC | Human IgG1 |
| HPAB-0235LY | Human Anti-PDGFRA Recombinant Antibody (clone 2.998.2) | Inhib, FC | Human IgG1 |
| HPAB-0236LY | Human Anti-PDGFRA Recombinant Antibody (clone 2.84.3) | Inhib, FC | Human IgG1 |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-878 | Anti-Human CD140a Recombinant Antibody (Tovetumab) | ELISA, FC, IP, FuncS, IF, Neut, WB | IgG2 - kappa |
| TAB-1063CL | Human Anti-PDGFRA Recombinant Antibody (TAB-1063CL) | FuncS | Human antibody |
| TAB-1063CL-S(P) | Human Anti-PDGFRA Recombinant Antibody; scFv Fragment (TAB-1063CL-S(P)) | ELISA | Human scFv |
| TAB-1063CL-F(E) | Human Anti-PDGFRA Recombinant Antibody; Fab Fragment (TAB-1063CL-F(E)) | ELISA | Human Fab |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NEUT-1848CQ | Recombinant Rat Anti-Pdgfra Antibody (APA5) | FC, FuncS, IHC-Fr, Neut, WB | IgG2a, κ |
| NEUT-1849CQ | Recombinant Mouse Anti-PDGFRA Antibody (CBL458) | WB, IHC, Neut | IgG1 |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOR-2637 | Hi-Affi™ Recombinant Rabbit Anti-PDGFRA Monoclonal Antibody (DS2637AB) | WB | IgG |
| MOR-4662 | Hi-Affi™ Recombinant Rabbit Anti-PDGFRA Monoclonal Antibody (TH176DS) | WB, IF, ICC, ChIP | IgG |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-0232LY-S(P) | Human Anti-PDGFRA Recombinant Antibody (clone 2.175.3); scfv Fragment | Inhib, FC | Human scfv |
| HPAB-0233LY-S(P) | Human Anti-PDGFRA Recombinant Antibody (clone 2.451.1.1); scfv Fragment | Inhib, FC | Human scfv |
| HPAB-0234LY-S(P) | Human Anti-PDGFRA Recombinant Antibody (clone 2.449.1.3); scfv Fragment | Inhib, FC | Human scfv |
| HPAB-0235LY-S(P) | Human Anti-PDGFRA Recombinant Antibody (clone 2.998.2); scfv Fragment | Inhib, FC | Human scfv |
| HPAB-0236LY-S(P) | Human Anti-PDGFRA Recombinant Antibody (clone 2.84.3); scfv Fragment | Inhib, FC | Human scfv |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-0232LY-F(E) | Human Anti-PDGFRA Recombinant Antibody (clone 2.175.3); Fab Fragment | Inhib, FC | Human Fab |
| HPAB-0233LY-F(E) | Human Anti-PDGFRA Recombinant Antibody (clone 2.451.1.1); Fab Fragment | Inhib, FC | Human Fab |
| HPAB-0234LY-F(E) | Human Anti-PDGFRA Recombinant Antibody (clone 2.449.1.3); Fab Fragment | Inhib, FC | Human Fab |
| HPAB-0235LY-F(E) | Human Anti-PDGFRA Recombinant Antibody (clone 2.998.2); Fab Fragment | Inhib, FC | Human Fab |
| HPAB-0236LY-F(E) | Human Anti-PDGFRA Recombinant Antibody (clone 2.84.3); Fab Fragment | Inhib, FC | Human Fab |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| AFC-TAB-192 | Afuco™ Anti-PDGFRA ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-192) | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
| AFC-TAB-878 | Afuco™ Anti-PDGFRA ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-878) | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0425-FY164 | Human Anti-PDGFRA (clone 2.175.3) scFv-Fc Chimera | Inhib, FC | Human IgG1, scFv-Fc |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0425-YC216 | Recombinant Anti-PDGFRA Vesicular Antibody, EV Displayed (VS-0425-YC216) | ELISA, FC, Neut, Cell-uptake |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0525-XY5274 | Anti-PDGFRA Immunohistochemistry Kit | IHC | |
| VS-0525-XY5275 | Anti-Mouse PDGFRA Immunohistochemistry Kit | IHC | |
| VS-0525-XY5276 | Anti-Rat PDGFRA Immunohistochemistry Kit | IHC |
Specific Inquiry
Add to compare
See Our Custom Production in Action
Popular Products
Application: FC, IP, ELISA, Neut, FuncS, IF, WB
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
-2.jpg)
Application: IB, ELISA, FC, FuncS
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: ELISA, FC, WB, Inhib, IHC
Application: ELISA, Vaccine, FuncS
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
